Press Releases 

Helomics Announces Second Phase of Realignment Towards a Research and Clinical Products Company in P

Helomics® Corporation, a privately-held, personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services, announced today the start of a second phase of corporate realignment towards becoming an integrated clinical research and clinical products company. During this restructuring the laboratory operations at Helomics, including the processing of its ChemoFx, GeneFX, BioSpeciFx, CellFx and DEFENDER tumor profiling tests, will continue at full capacity. As part of this second realignment phase, Helomics will restructure its R&D, operations, and sales and marketing to refocus its efforts on the central buying and

Archive
 Follow Us
  • LinkedIn Social Icon
  • Facebook Basic Square
  • Twitter Basic Square

© 2020 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon